Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid plus dexamethasone in relapsed or refractory multiple myeloma
NCT00056160Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2003
- Primary completion
- Nov 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Jan 2003; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00056160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056160.